检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]吉林大学畜牧兽医学院微生物与免疫学实验室,吉林长春130000
出 处:《微生物学杂志》2011年第5期97-100,共4页Journal of Microbiology
摘 要:初步确定高效价冻干人用狂犬病疫苗(6.0 IU/剂)暴露后免疫程序。制备高效价的冻干人用狂犬病疫苗(6.0 IU/剂),以狂犬病街毒CNX8601和BD06分别攻击小鼠和比格犬的咬肌,接种不同效价的狂犬病疫苗,以RFFIT法检测中和抗体,根据动物死亡情况,计算暴露后疫苗保护率,对不同效价的疫苗进行中和抗体测定和保护率统计分析。在以小鼠为实验动物的疫苗保护率研究中,冻干人用狂犬病疫苗(3.1 IU/剂)0/3/7/14/28免疫程序的保护率为40.6%,高效价的冻干人用狂犬病疫苗(6.0 IU/剂)0/3/14免疫程序的保护率为56.2%,中和抗体比较,P<0.05,2组间有显著性差异;在以比格犬为实验动物的保护效果研究中,冻干人用狂犬病疫苗的保护率(3.1 IU/剂)为70%;高效价的冻干人用狂犬病疫苗(6.0 IU/剂)的保护率为80%,中和抗体的比较,P>0.05,没有显著性差异。高效价冻干人用狂犬病疫苗暴露后免疫程序可初步确定为0、3、14 d免疫。The PEP (post-exposure prophylaxis ) schedule of freeze-dried rabies vaccine with high potency (HPRabV) (6.0 IU/dose) was established preliminarily. The HPRabV (6.0 IU/dose) was prepared, the BALB/c mice and Beagles were challenged with the street virus CNX8601 or BD06 at the masseter muscle, then inoculated with rabies vaccine of different potency (3.1 IU/dose or 6.0 IU/dose). The rapid fluorescent focus inhibition test (RFFIT) was used to detect rabies virus neutralizing antibody ( RVNA ) in mouse and beagles sera. The protection efficacy against street rabies virus was calculated according to the animal' s death rates and carried out statistic analyses. The results showed that HPRabV (6.0 IU/dose) could induce the more vigorous production of RVNA in BALB/ c mice and beagles. The data indicated that the three-shot HPRabV could achieve a higher protection rate (survival rate 56.2% ) by 0/3/14 PEP schedule as compared with that of the RabV group ( survival rate 40.6% ) by 0/3/7/ 14/28 PEP schedule in mice, neutralizing antibody comparison, P 〈 0.05, the differences between the two groups were significant. The data also indicated that the HPRabV could achieve a survival rate (80. 0% ) vs. RabV (70.0%) by PEP in beagles, neutralizing antibody comparison, P 〉 0.05, the differences were not significant. Therefore, it is concluded that the PEP schedule of HPRabV for human use could initially decide the prophylactic vaccination at 0, 3, 14 days.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15